Background
Methods
Results
Conclusions
Trial Registry
Key Words
Abbreviations:
AHI ( apnea-hypopnea index), CV ( cardiovascular), ESS ( Epworth Sleepiness Scale), ODI ( oxygen desaturation index)References
- Upper airway collapsibility is associated with obesity and hyoid position.Sleep. 2014; 37: 1673-1678
- Obesity and sleep-disordered breathing—when two 'bad guys' meet.QJM. 2014; 107: 949-954
- Influence of sleep on genioglossus muscle activation by negative pressure in normal men.Am Rev Respir Dis. 1993; 148: 597-605
- Obstructive sleep apnea and energy balance regulation: a systematic review.Sleep Med Rev. 2017; 34: 59-69
- Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment.Eur Respir J. 2003; 22: 251-257
- Associations between macronutrient intake and obstructive sleep apnoea as well as self-reported sleep symptoms: results from a cohort of community dwelling Australian men.Nutrients. 2016; 8: 207
- Lack of regular exercise, depression, and degree of apnea are predictors of excessive daytime sleepiness in patients with sleep apnea: sex differences.J Clin Sleep Med. 2008; 4: 19-25
- Relationship between the quality of life and the severity of obstructive sleep apnea syndrome.Braz J Med Biol Res. 2008; 41: 908-913
- Association of physical activity with sleep-disordered breathing.Sleep Breath. 2007; 11: 149-157
- The effect of continuous positive airway pressure treatment on physical activity in patients with obstructive sleep apnoea: a randomised controlled trial.Sleep Med. 2009; 10: 1056-1058
- Energy expenditure in obstructive sleep apnea.Sleep. 1995; 18: 180-187
- Energy expenditure in obstructive sleep apnea: effects of treatment with continuous positive airway pressure.Am J Physiol. 1996; 271: E1036-E1043
- Resting metabolic rate and anthropometric measurements in male sleep apnea patients.Intern Med. 2011; 50: 833-838
- Continuous positive airway pressure treatment results in weight loss in obese and overweight patients with obstructive sleep apnea.J Am Diet Assoc. 1997; 97: 896-897
- Impact of treatment with continuous positive airway pressure (CPAP) on weight in obstructive sleep apnea.J Clin Sleep Med. 2013; 9: 989-993
- Does CPAP lead to change in BMI?.J Clin Sleep Med. 2008; 4: 205-209
- Effects of CPAP on body weight in patients with obstructive sleep apnoea: a meta-analysis of randomised trials.Thorax. 2015; 70: 258-264
- The Sleep Apnea cardioVascular Endpoints (SAVE) trial: rationale, ethics, design, and progress.Sleep. 2015; 38: 1247-1257
- CPAP for prevention of cardiovascular events in obstructive sleep apnea.N Engl J Med. 2016; 375: 919-931
Australian New Zealand Clinical Trials Registry. ACTRN12608000409370. Sleep Apnea cardioVascular Endpoints Study - Investigating the Effectiveness of Treatment With CPAP vs Standard Care in Reducing CV Morbidity and Mortality in Patients With Co-existing CV Disease and Moderate-severe Obstructive Sleep Apnea. (SAVE). www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12608000409370. Verification date February 2015; registered August 2008; last updated November 2016. Accessed October 31, 2018.
- Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial.JAMA. 2012; 307: 2161-2168
- Guidelines for the Management of Absolute Cardiovascular Disease Risk.National Stroke Foundation of Australia, Australia2012 (978-0-9872830-1-6)
- Reducing Risk in Heart Disease: An Expert Guide to Clinical Practice for Secondary Prevention of Coronary Heart Disease.National Heart Foundation of Australia, Melbourne, Australia2012 (978-1-74345-016-1)
- 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).Eur Heart J. 2016; 37: 2315-2381
- AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.Circulation. 2011; 124: 2458-2473
- Impact of the Provider and Healthcare team Adherence to Treatment Guidelines (PHAT-G) intervention on adherence to national obesity clinical practice guidelines in a primary care centre.J Eval Clin Pract. 2015; 21: 300-306
World Heart Federation. Secondary Cardiovascular Disease Prevention and Control. www.worldheart.org. World Heart Federation, Geneva, Switzerland: 2014. Accessed February 1, 2018.
- Association between treated and untreated obstructive sleep apnea and risk of hypertension.JAMA. 2012; 307: 2169-2176
- Obstructive sleep apnea as a risk factor for type 2 diabetes.Am J Med. 2009; 122: 1122-1127
- Association of incident obstructive sleep apnoea with outcomes in a large cohort of US veterans.Thorax. 2015; 70: 888-895
- Longitudinal study of moderate weight change and sleep-disordered breathing.JAMA. 2000; 284: 3015-3021
- Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults.J Clin Sleep Med. 2009; 5: 263-276
- Management of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians.Ann Intern Med. 2013; 159: 471-483
- Obstructive sleep apnoea in adults: a common chronic condition in need of a comprehensive chronic condition management approach.Sleep Med Rev. 2013; 17: 349-355
- CPAP, weight loss, or both for obstructive sleep apnea.N Engl J Med. 2014; 370: 2265-2275
- Contribution of socioeconomic factors to the variation in body-mass index in 58 low-income and middle-income countries: an econometric analysis of multilevel data.Lancet Glob Health. 2018; 6: e777-e786
Article Info
Publication History
Footnotes
FUNDING/SUPPORT: The Sleep Apnea Cardiovascular Endpoints (SAVE) trial was funded by project grants [1006501 and 1060078] from the National Health and Medical Research Council of Australia and by the Respironics Sleep and Respiratory Research Foundation and Philips Respironics. Supplementary funding was provided by Fisher & Paykel Healthcare and the Australasian Sleep Trials Network [enabling grant 343020 from the National Health and Medical Research Council]. In-kind donations were provided by Respironics for the CPAP equipment and by ResMed for the sleep apnea diagnostic devices. This substudy was supported by a grant [National Natural Science Foundation of China 81870077] to Q. O.
Dr Mukherjee is currently with the Adelaide Institute for Sleep Health, Flinders University, Adelaide, SA, Australia; and the Sleep Health Service, Respiratory and Sleep Services, Southern Adelaide Local Health Network, Bedford Park, SA, Australia.